Submit a Manuscript to the Journal

All Life

For an Article Collection on

Understanding Rare Diseases for Implementing Personalized Medicine and Addressing Sustainable Development Goal 3

Manuscript deadline
30 April 2025

Cover image - All Life

Article collection guest advisor(s)

Prof. Amar Abderrahmani, Lille University
[email protected]

Submit an ArticleVisit JournalArticles

Understanding Rare Diseases for Implementing Personalized Medicine and Addressing Sustainable Development Goal 3

The resolution adopted by general assembly of United Nations on 16th December 2021 has made the rights protection, society integration, well-being and health of persons living with a rare disease as one the key priorities for reaching the Sustainable Development Goals 3 (SDG3). There are approximately 300 million persons living with a rare disease worldwide, many of whom are children.

The World Health Organization estimates that 10 out of every 1000 individuals are impacted by rare monogenic diseases. So far, for many of these rare diseases, there is still some trouble in providing definitive diagnoses and treatment options. Improvement in the search for mutations using cutting-edge sequencing technology and the study of mutations compelling in silico, in vitro and in vivo modelling approaches are essential for posing the right diagnosis, therapeutic strategies and for prescribing the adequate medicine. This research will enable the implementation of personalized medicine, which will give a better chance to manage and treat the disorders that previously meant a death sentence.

In this Article Collection, All Life addresses SDG3: Good Health and Well-Being through innovative open scientific research addressing genetic diseases or new methods of personalized medicine under the sections “Pharmacology & Pharmaceutics ”, “Computational Life Sciences, Bioinformatics & System Biology”, and “Epidemiology, Genetics & Genomics”. This Article Collection will accept original research articles, reviews, short communications, data notes, and commentaries on topics including, but not limited to:

  1. Advances in sequencing technologies and diagnosis
  2. Identification of novel genetic syndrome
  3. Unravelling the diseases mechanisms using “omics” approaches
  4. Computational modelling in mutation effects
  5. Novel computational programs and methods
  6. Statistics used in the field of epidemiology and genetics
  7. Novel mathematical models for predicting prognosis and complications
  8. Animal and cellular models of rare diseases
  9. Large-scale studies providing new insight in rare disease diagnosis, disease mechanism, and treatment strategies
  10. Current and new drugs treating rare diseases

­­All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisor for this Collection will not be handling the manuscripts (unless they are an Editorial Board member).

Please review the journal scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is 30 April 2025.

Please contact Ashley Ambros at [email protected] with any queries and discount codes regarding this Article Collection.

Please be sure to select the appropriate Article Collection from the drop-down menu in the submission system, and please select “Pharmacology & Pharmaceutics”, “Computational Life Sciences, Bioinformatics and System Biology”, OR “Epidemiology, Genetics & Genomics” from the list of available sections during submission. Failure to select the appropriate Article Collection or Section name can result in delays.

Prof. Dr. Amar ABDERRAHMANI is Full Professor of Cell and Molecular Biology at the Faculty of Medicine at Lille University. He is currently the head of the team devoted to nanomaterials for health in the institute of electronics, microelectronics, and nanotechnologies. He has a multidisciplinary background including a PhD and pharmacy graduation in Molecular genetics and pharmaceutical chemistry. AA has been honoured by several Swiss awards and in 2011, of National Chair of Excellence in beta-cell biology, bioscience and diabetes. AA has been member of several scientific committees of Diabetes Association.

Benefits of publishing open access within Taylor & Francis

Global marketing and publicity, ensuring your research reaches the people you want it to.

Article Collections bring together the latest research on hot topics from influential researchers across the globe.

Rigorous peer review for every open access article.

Rapid online publication allowing you to share your work quickly.

All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.